Figure 4.

Treatment with RK35 increases muscle strength in oculopharyngeal muscular dystrophy mice: Mice (n = 8–10) were administered with a weekly regimen of either saline or the RK35 antibody (10 mg/kg IP) for 10 weeks from 12‐week of age. (A) Forelimb grip strength was analysed and the average of 15 measurements per mouse, per group is plotted, bars representing standard error of the mean, with P‐values obtained by analysis of variance after a false discovery rate correction. (B–D) The left TA from all groups were mounted on a mechanotransducer and the sciatic nerve was excited (B) average max. force generated at increasing frequencies is plotted. (C) The average max. force generated at 180 Hz is plotted, with bars representing standard error of the mean. The gross muscle strength of the disease model mice treated with the antibody displayed an increased grip strength, although a similar effect was not observed in the control mice. (D) Maximal force values were normalized with the muscle cross‐sectional area to obtain specific force of TA at 180 Hz, and no significant differences observed between the groups. Data presented as mean ± standard error of the mean, with P‐values obtained by analysis of variance after a false discovery rate correction (*P < 0.05 and **P < 0.01). TA, tibialis anterior.